AI Analysis | Feedback

Here are 1-3 brief analogies for Corvus Pharmaceuticals (CRVS):

1. A clinical-stage Genentech (before its acquisition by Roche), but solely focused on developing innovative cancer therapies.

2. An early-stage pharmaceutical company aiming to develop breakthrough cancer drugs, much like a specialized division of Bristol Myers Squibb's oncology pipeline.

3. A startup biotech like an early Gilead Sciences, but with its entire focus on discovering and advancing novel drugs specifically for oncology.

AI Analysis | Feedback

• CPI-818: An oral, small molecule ITK inhibitor currently in clinical development for the treatment of various T-cell lymphomas and potential autoimmune diseases.
• CPI-006 (Morb-201): A PIM kinase inhibitor being developed by a subsidiary for the treatment of infectious diseases, including Covid-19 related acute respiratory distress syndrome.

AI Analysis | Feedback

Corvus Pharmaceuticals (symbol: CRVS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. As a company primarily in the research and development phase, Corvus Pharmaceuticals does not currently have any FDA-approved commercial products on the market.

Therefore, Corvus Pharmaceuticals does not have "major customers" in the traditional sense, meaning they do not sell products to other companies (e.g., pharmacies, hospitals, distributors) or directly to individuals (patients). Their revenue, when generated, typically comes from:

1. Collaboration and Licensing Agreements: In the past, and potentially in the future, Corvus has entered or may enter into agreements with larger pharmaceutical or biotechnology companies for the development, commercialization, or regional rights to their product candidates. In such scenarios, the partner company would be a "customer" providing upfront payments, milestone payments, or royalties. However, as of recent filings, Corvus does not have significant active collaboration revenue.
2. Grants: From government agencies or non-profit organizations for research and development activities.

Currently, Corvus Pharmaceuticals primarily funds its operations through equity financing (issuing shares) and other financial activities to advance its drug pipeline. They do not report product sales revenue.

AI Analysis | Feedback

• Everest Clinical Research Corporation

AI Analysis | Feedback

Richard A. Miller, M.D. Co-Founder, President and CEO

Dr. Miller co-founded Corvus Pharmaceuticals in 2014 and has served as its President and Chief Executive Officer since. Prior to Corvus, he was the co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Pharmacyclics was acquired by AbbVie for $21 billion in May 2015. Before Pharmacyclics, Dr. Miller was a co-founder, Vice President, and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma, culminating in the development of rituximab. He has also founded other private and public biotech companies and held C-suite roles.

Leiv Lea Chief Financial Officer

Mr. Lea has served as the Chief Financial Officer of Corvus Pharmaceuticals. He previously held the same role as Chief Financial Officer at Pharmacyclics from 1998 to 2008.

Jeffrey Arcara Chief Business Officer

Mr. Arcara joined Corvus in 2024 as Chief Business Officer. He is responsible for leading the company's corporate strategy, business development, portfolio strategy, and new product planning. With over 30 years of commercial expertise in the biopharmaceutical industry, Mr. Arcara has held commercial leadership roles of increasing responsibility across various disease areas, including as Senior Vice President, Head Global Marketing & Portfolio and Strategy for the specialty and biosimilars business at Teva Pharmaceuticals.

William Ben Jones, Ph.D. Senior Vice President, Pharmaceutical Development

Dr. Jones served as Director of Global Regulatory Affairs in Sanofi U.S.'s oncology business unit from December 2012 to December 2014. Prior to that, he was Director of Project Management & Regulatory at Pharmacyclics, where he played a principal role in the development of ibrutinib. He also held positions as Associate Director of Development at Plexxikon and Senior Project Manager at Vertex Pharmaceuticals.

Gabriel Luciano Vice President Clinical Operations

Mr. Luciano joined Corvus in 2018 and has served as Vice President of Clinical Operations since 2021. He was Senior Director of Clinical Operations at Pharmacyclics from 2012 to 2017, where he played a principal role in the initial clinical development and marketing approvals for ibrutinib. From 2008 to 2011, he was Senior Clinical Trial Manager at Seattle Genetics, supporting the initial clinical trial development and marketing approvals for brentuximab vedotin.

AI Analysis | Feedback

1. Financial Instability and Dilution Risk: Corvus Pharmaceuticals faces significant financial risk due to limited cash reserves, ongoing operating losses, and a history of needing to raise additional capital. The company's management has even expressed "substantial doubt about the company's ability to continue as a going concern". It anticipates needing additional funding, potentially by the first quarter of 2026, and its current cash runway is projected to last into the fourth quarter of 2026. This often leads to the issuance of new shares, which can dilute the ownership of existing shareholders.
2. Clinical Trial and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Corvus's success is entirely dependent on the successful development, regulatory approval, and eventual commercialization of its product candidates. There is inherent uncertainty and high risk in clinical trials; product candidates may fail to demonstrate sufficient efficacy or safety, experience delays, or not receive regulatory approval from agencies like the FDA or comparable foreign authorities. Mixed or unfavorable clinical trial results for its lead asset, soquelitinib, in indications such as atopic dermatitis or peripheral T-cell lymphoma (PTCL) could significantly impact the company's prospects.
3. Market Prospects and Intense Competition: Even if Corvus's product candidates achieve regulatory approval, the company faces challenges in commercialization due to a highly competitive market, particularly in areas like atopic dermatitis where established and successful treatments already exist. The commercial viability of its drugs will depend on factors such as demonstrated superiority or unique benefits over existing therapies, market acceptance, and the ability to compete effectively against larger pharmaceutical companies with greater resources.

AI Analysis | Feedback

AI Analysis | Feedback

Corvus Pharmaceuticals' main product candidate, soquelitinib (CPI-818), targets peripheral T cell lymphoma (PTCL) and atopic dermatitis. The addressable market for PTCL is estimated as follows:

• The global T-cell lymphoma market was valued at approximately USD 2.12 billion in 2023.
• Another estimate for the PTCL market is around half a billion dollars (2021 figures).
• In the United States, there are an estimated 10,000 to 15,000 cases of T-cell lymphoma per year, with Peripheral T-cell lymphoma – not otherwise specified (PTCL–NOS) having an incidence of about 2,500 cases per year.

For Corvus Pharmaceuticals' other product candidates, ciforadenant (CPI-444) and mupadolimab (CPI-006), specific addressable market sizes for their targeted indications (renal cell cancer, metastatic castration-resistant prostate cancer, non-small cell lung cancer, and COVID-19) are null.

AI Analysis | Feedback

Corvus Pharmaceuticals (CRVS), a clinical-stage biopharmaceutical company, is poised for potential future revenue growth primarily through the advancement and commercialization of its pipeline assets, particularly soquelitinib, and through strategic partnerships. As a company in the clinical stage, its revenue generation will largely depend on regulatory approvals and subsequent market penetration of its drug candidates.

Here are 3-5 expected drivers of future revenue growth for Corvus Pharmaceuticals over the next 2-3 years:

1. Commercialization of Soquelitinib in Peripheral T-cell Lymphoma (PTCL): Corvus is actively enrolling patients in a registrational Phase 3 clinical trial for soquelitinib in patients with relapsed/refractory PTCL. Positive results from this trial and subsequent regulatory approval would enable the company to bring its lead candidate to market, establishing a significant new revenue stream.

2. Market Entry of Soquelitinib for Atopic Dermatitis: The company is making significant progress with soquelitinib for the treatment of moderate to severe atopic dermatitis, with a Phase 2 clinical trial anticipated to commence in early Q1 2026. The atopic dermatitis market is substantial, projected to reach $29.88 billion by 2030, representing a considerable potential revenue opportunity upon successful development and commercialization.

3. Expansion of Soquelitinib into Additional Indications: Beyond PTCL and atopic dermatitis, Corvus is exploring the broader applicability of soquelitinib. The drug is currently in a Phase 2 clinical trial for Autoimmune Lymphoproliferative Syndrome (ALPS), a rare genetic disease, and the company plans to initiate a solid tumor clinical trial later in 2025. Successful development in these additional areas would diversify its product portfolio and expand its total addressable market, driving further revenue growth.

4. Revenue from Strategic Partnerships and Licensing Agreements: Corvus currently generates revenue primarily through collaborations, licensing agreements, and milestone payments. Its partnership with Angel Pharmaceuticals, which licensed rights to Corvus's clinical-stage candidates in greater China and global rights to preclinical BTK inhibitor programs, is an existing source. Future milestone achievements from this and potentially new collaborations or licensing deals would contribute to the company's revenue.

AI Analysis | Feedback

Share Issuance

• Corvus Pharmaceuticals received $54.3 million in proceeds from the exercise of common stock warrants in May 2024.
• The number of shares outstanding significantly increased, with 74,681,872 shares as of November 4, 2025, compared to 49,038,582 shares outstanding as of March 19, 2024, and 48,025,274 weighted average common shares outstanding in 2023.
• The company established a $100.0 million at-the-market equity offering program in August 2024, although no sales had been made under this program as of September 30, 2025.

Inbound Investments

• Corvus Pharmaceuticals launched Angel Pharmaceuticals through a collaboration that included investments from Chinese investors.
• Angel Pharmaceuticals licensed the rights to develop and commercialize Corvus's three clinical-stage candidates (soquelitinib, ciforadenant, and mupadolimab) in greater China.

Outbound Investments

• Corvus Pharmaceuticals holds a 49.7% equity stake in Angel Pharmaceuticals.
• The equity method investment in Angel Pharmaceuticals resulted in non-cash losses of $0.3 million for the three months ended September 30, 2025, and $1.3 million for the nine months ended September 30, 2025.

Capital Expenditures

• Capital expenditures for Corvus Pharmaceuticals were approximately -$149,000 in the last 12 months.
• The primary focus of the company's expenditures is on research and development (R&D) for its clinical-stage product candidates, with R&D expenses totaling $8.5 million for the three months ended September 30, 2025, primarily due to higher clinical trial and manufacturing costs.